Journal: Frontiers in immunology

Article Title: Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.

doi: 10.3389/fimmu.2023.1171308

Figure Lengend Snippet: FIGURE 1 The expression of CD40, CD40L, ICOS, and ICOSL in nasal tissues of patients with ECRS and non-eCRS. (A) The representative immunohistochemistry stainings of CD40, CD40L, ICOS, and ICOSL. Original magnification, ×400. (B) The mean numbers of CD40+ (non-eCRS, n = 19; ECRS, n = 9), CD40L+ (non-eCRS, n = 15; ECRS, n = 9), ICOS+ (non-eCRS, n = 12; ECRS, n = 8), and ICOSL+ (non-eCRS, n = 15; ECRS, n = 10) cells in nasal tissues.

Article Snippet: Blood was treated with red blood cell lysis buffer and then incubated for 24 h at 37°C with either recombinant human CD40L protein (rhCD40L, 5 μg/ml; R&D Systems, Minneapolis, MN, USA, 6420-CL-025) or recombinant human ICOS protein (rhICOS, 10 μg/ml; R&D Systems, Minneapolis, MN, USA, 169-CS-050).

Techniques: Expressing, Immunohistochemistry

Journal: Frontiers in immunology

Article Title: Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.

doi: 10.3389/fimmu.2023.1171308

Figure Lengend Snippet: FIGURE 2 The correlation among the levels of CD40, CD40L, ICOS, and ICOSL in nasal tissues of patients with CRS. N = 21, 26, 25, 20, 25, and 21 in (A–F).

Article Snippet: Blood was treated with red blood cell lysis buffer and then incubated for 24 h at 37°C with either recombinant human CD40L protein (rhCD40L, 5 μg/ml; R&D Systems, Minneapolis, MN, USA, 6420-CL-025) or recombinant human ICOS protein (rhICOS, 10 μg/ml; R&D Systems, Minneapolis, MN, USA, 169-CS-050).

Techniques:

Journal: Frontiers in immunology

Article Title: Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.

doi: 10.3389/fimmu.2023.1171308

Figure Lengend Snippet: FIGURE 4 The correlation among the levels of CD40, CD40L, ICOS, and ICOSL nasal polyp of patients with edematous CRS. N = 13, 15, 15, 13, 15, and 13 in (A–F).

Article Snippet: Blood was treated with red blood cell lysis buffer and then incubated for 24 h at 37°C with either recombinant human CD40L protein (rhCD40L, 5 μg/ml; R&D Systems, Minneapolis, MN, USA, 6420-CL-025) or recombinant human ICOS protein (rhICOS, 10 μg/ml; R&D Systems, Minneapolis, MN, USA, 169-CS-050).

Techniques:

Journal: Frontiers in immunology

Article Title: Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.

doi: 10.3389/fimmu.2023.1171308

Figure Lengend Snippet: FIGURE 3 The expression of CD40-CD40L and ICOS-ICOSL in different histological patterns of patients with CRS. (A) The percentage of six different histological patterns in ECRS (n = 10) and non-eCRS (n = 21), respectively. (B) The percentage of three histological patterns (edematous: edematous, edematous + fibrotic, and edematous + hyperplasia; fibrotic: fibrotic and edematous + fibrotic; hyperplasia: hyperplasia and edematous + hyperplasia) in ECRS (n = 10) and non-eCRS (n = 21). (C–F) Expression levels of ICOSL (non-edematous, n = 7; edematous, n = 12), ICOS (non- edematous, n = 10; edematous, n = 16), CD40 (non-edematous, n = 13; edematous, n = 15) and CD40L (non-edematous, n = 10; edematous, n = 15) in nasal tissues of patients with edematous and non-edematous CRS.

Article Snippet: Blood was treated with red blood cell lysis buffer and then incubated for 24 h at 37°C with either recombinant human CD40L protein (rhCD40L, 5 μg/ml; R&D Systems, Minneapolis, MN, USA, 6420-CL-025) or recombinant human ICOS protein (rhICOS, 10 μg/ml; R&D Systems, Minneapolis, MN, USA, 169-CS-050).

Techniques: Expressing

Journal: Frontiers in immunology

Article Title: Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.

doi: 10.3389/fimmu.2023.1171308

Figure Lengend Snippet: FIGURE 6 (A–D) The correlation between expression levels of nasal tissues CD40 (n = 28), CD40L (n = 25), ICOS (n = 21), ICOSL (n = 27), and blood eosinophil count. (E, F) The correlation between expression levels of ICOS (n = 19) and ICOSL (n = 24) in nasal tissues and Lund–Mackay score.

Article Snippet: Blood was treated with red blood cell lysis buffer and then incubated for 24 h at 37°C with either recombinant human CD40L protein (rhCD40L, 5 μg/ml; R&D Systems, Minneapolis, MN, USA, 6420-CL-025) or recombinant human ICOS protein (rhICOS, 10 μg/ml; R&D Systems, Minneapolis, MN, USA, 169-CS-050).

Techniques: Expressing

Journal: Frontiers in immunology

Article Title: Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.

doi: 10.3389/fimmu.2023.1171308

Figure Lengend Snippet: FIGURE 5 Association between levels of CD40-CD40L, ICOS-ICOSL, and eosinophil in nasal tissues of CRS. (A) The correlation analysis between the number of CD40+ (n = 28), CD40L+ (n = 25), ICOS+ (n = 21), ICOSL+ (n = 27) cells, and tissue eosinophils levels in CRS. (B, C) The co-localization of eosinophils (PRG2, 488) and CD40 (CY3) as well as ICOSL (CY3) assessed by immunofluorescence in patients with ECRS. Original magnification, ×400.

Article Snippet: Blood was treated with red blood cell lysis buffer and then incubated for 24 h at 37°C with either recombinant human CD40L protein (rhCD40L, 5 μg/ml; R&D Systems, Minneapolis, MN, USA, 6420-CL-025) or recombinant human ICOS protein (rhICOS, 10 μg/ml; R&D Systems, Minneapolis, MN, USA, 169-CS-050).

Techniques:

Journal: Frontiers in immunology

Article Title: Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.

doi: 10.3389/fimmu.2023.1171308

Figure Lengend Snippet: FIGURE 7 The effect of CD40-CD40L and ICOS-ICOSL pathways on eosinophil activation. Peripheral blood of patients with ECRS was stimulated with medium alone (Control, circle, n = 5), IgG (5 µg/ml, rectangle, n = 7), (A) rhCD40L (5 µg/ml, triangle, n = 10) or (B) rhICOS (10 µg/ml, triangle) for 24 h. Then, CD69 expression on eosinophils was detected by flow cytometry. Activated eosinophils were defined as CD45+CD16−CD69+ cells. The percentage of activated eosinophils after different stimulation.

Article Snippet: Blood was treated with red blood cell lysis buffer and then incubated for 24 h at 37°C with either recombinant human CD40L protein (rhCD40L, 5 μg/ml; R&D Systems, Minneapolis, MN, USA, 6420-CL-025) or recombinant human ICOS protein (rhICOS, 10 μg/ml; R&D Systems, Minneapolis, MN, USA, 169-CS-050).

Techniques: Activation Assay, Control, Expressing, Cytometry

Journal: Scientific Reports

Article Title: Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma

doi: 10.1038/s41598-025-88671-4

Figure Lengend Snippet: Relative expression of genes expression in GBM tissues. Expression levels of WTAP and ZC3H13 genes were compared with those of the control group on GBM tissues, 10 GBM and adjacent tissues, respectively ( A ). The expression levels of siRNA WTAP and overexpression ZC3H13 genes ( B and C ). The expression levels of CD27, CD70, CD80, CD86, ICOS, CTLA4, and LAG3 in siRNA WTAP and overexpression ZC3H13 were demonstrated in Fig. 9D and F, respectively. The result were determined by qRT-PCR. The data are mean ± standard deviation of six replicate experiments. * P < 0.05, **P < 0.01 and ***P < 0.001 compared with the corresponding control values.

Article Snippet: After blocking with 5% nonfat milk, the membranes were immunoblotted with the primary antibodies: WTAP (A04296-2, Boster Biotech, Wuhan, China), CD27 (A01148-2, Boster Biotech), CD70 (A02853-2, Boster Biotech), CD80 (A00196-3, Boster Biotech), CD86(BM4121, Boster Biotech), ICOS (A00291-2, Boster Biotech), CTLA4 (A00020-1, Boster Biotech), LAG3 (M02869-2, Boster Biotech), Beta-actin (BM3873, Boster Biotech).

Techniques: Expressing, Control, Over Expression, Quantitative RT-PCR, Standard Deviation